RET oncogenic mutations give rise to PCC in patients with MEN2 and are found in up to 5% of sporadic PCC, where they promote constitutive RET activation and downstream signaling (Horton et al., 2022; Le Hir et al., 2000; Mulligan, 2018; Takaya et al., 1996a; Takaya et al., 1996b). The gene discussed is RET; the disease is adrenal gland pheochromocytoma.